Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Significant Decrease in Short Interest

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) saw a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling 148,835 shares, a decrease of 21.3% from the February 12th total of 189,121 shares. Based on an average daily volume of 129,793 shares, the days-to-cover ratio is currently 1.1 days. Approximately 0.8% of the company’s stock are sold short. Approximately 0.8% of the company’s stock are sold short. Based on an average daily volume of 129,793 shares, the days-to-cover ratio is currently 1.1 days.

Analysts Set New Price Targets

ARTV has been the subject of several recent research reports. Jefferies Financial Group upgraded Artiva Biotherapeutics to a “strong-buy” rating in a research note on Tuesday, November 18th. Needham & Company LLC restated a “buy” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a research note on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, January 27th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Artiva Biotherapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.

Institutional Trading of Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARTV. Citadel Advisors LLC lifted its position in shares of Artiva Biotherapeutics by 419.3% during the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after buying an additional 644,658 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of Artiva Biotherapeutics by 14,463.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after buying an additional 117,733 shares during the last quarter. Renaissance Technologies LLC raised its stake in Artiva Biotherapeutics by 46.8% during the 4th quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock worth $498,000 after acquiring an additional 37,053 shares in the last quarter. Marshall Wace LLP acquired a new stake in Artiva Biotherapeutics during the 4th quarter worth $341,000. Finally, Jane Street Group LLC purchased a new stake in Artiva Biotherapeutics in the second quarter valued at $67,000.

Artiva Biotherapeutics Stock Performance

NASDAQ:ARTV opened at $6.18 on Friday. The stock has a 50-day simple moving average of $4.77 and a 200-day simple moving average of $3.98. The stock has a market cap of $152.75 million, a P/E ratio of -1.81 and a beta of 2.16. Artiva Biotherapeutics has a 1 year low of $1.47 and a 1 year high of $7.75.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Tuesday, March 10th. The company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.03. On average, equities research analysts predict that Artiva Biotherapeutics will post -4.95 EPS for the current year.

Key Headlines Impacting Artiva Biotherapeutics

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: HC Wainwright raised several multi‑period EPS forecasts, trimming projected losses across FY2026–FY2030 (e.g., FY2026 from ($4.26) to ($4.18); FY2027 from ($1.76) to ($1.61); FY2029 from ($0.74) to ($0.66); FY2030 from ($0.41) to ($0.36)). These revisions suggest modest improvement in the firm’s modeled outlook and can be supportive for the stock.
• Positive Sentiment: HC Wainwright also upgraded near‑term quarter forecasts for Q1–Q3 2026 (Q1: ($0.96) → ($0.89); Q2: ($1.05) → ($0.94); Q3: ($1.10) → ($1.06)), indicating better-than-previously-expected operating trajectory into 2026.
• Positive Sentiment: Needham & Company LLC initiated/issued a Buy rating for ARTV, which can attract demand from growth/biotech investors and provide short‑term upward pressure. Artiva Biotherapeutics (NASDAQ:ARTV) Earns Buy Rating from Needham & Company LLC
• Neutral Sentiment: The company released its full‑year 2025 financial results and business highlights on March 11; investors will parse revenue, cash runway, and program updates in the filing/press release for longer‑term implications. Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
• Neutral Sentiment: Reported short‑interest data in mid‑March shows zero shares (and NaN changes), which appears to be a reporting anomaly and is not informative about true short pressure at this time.
• Negative Sentiment: HC Wainwright cut the Q4 2026 EPS view (worse) from ($1.16) to ($1.29), signaling a potentially weaker near‑term quarter that could weigh on sentiment if guidance or results mirror that pause.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.